Los Angeles Capital Management LLC Has $447,000 Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Los Angeles Capital Management LLC grew its stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 22.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 87,723 shares of the biotechnology company’s stock after purchasing an additional 16,000 shares during the period. Los Angeles Capital Management LLC owned about 0.13% of CytomX Therapeutics worth $447,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Massachusetts Financial Services Co. MA boosted its stake in shares of CytomX Therapeutics by 0.9% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 295,718 shares of the biotechnology company’s stock valued at $1,872,000 after purchasing an additional 2,535 shares in the last quarter. Liberty Wealth Management LLC raised its holdings in CytomX Therapeutics by 533.0% in the 2nd quarter. Liberty Wealth Management LLC now owns 3,165 shares of the biotechnology company’s stock valued at $500,000 after buying an additional 2,665 shares during the last quarter. ProShare Advisors LLC raised its holdings in CytomX Therapeutics by 12.2% in the 2nd quarter. ProShare Advisors LLC now owns 28,508 shares of the biotechnology company’s stock valued at $180,000 after buying an additional 3,100 shares during the last quarter. Rhumbline Advisers raised its holdings in CytomX Therapeutics by 5.2% in the 2nd quarter. Rhumbline Advisers now owns 64,176 shares of the biotechnology company’s stock valued at $406,000 after buying an additional 3,190 shares during the last quarter. Finally, Credit Suisse AG raised its holdings in CytomX Therapeutics by 8.9% in the 2nd quarter. Credit Suisse AG now owns 45,723 shares of the biotechnology company’s stock valued at $289,000 after buying an additional 3,718 shares during the last quarter. Institutional investors own 89.60% of the company’s stock.

A number of research analysts recently issued reports on the stock. Zacks Investment Research lowered shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 4th. BTIG Research assumed coverage on shares of CytomX Therapeutics in a report on Monday, November 15th. They issued a “buy” rating and a $16.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective (down previously from $12.00) on shares of CytomX Therapeutics in a report on Wednesday, December 22nd. Finally, Mizuho restated a “buy” rating and set a $16.00 price target on shares of CytomX Therapeutics in a report on Friday, November 5th. Two analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $11.67.

CytomX Therapeutics stock opened at $3.95 on Friday. The firm has a 50 day moving average price of $5.80 and a two-hundred day moving average price of $5.58. The firm has a market cap of $257.73 million, a price-to-earnings ratio of -3.24 and a beta of 0.59. CytomX Therapeutics, Inc. has a 52-week low of $3.67 and a 52-week high of $10.05.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Thursday, November 4th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.05). The company had revenue of $17.59 million during the quarter, compared to the consensus estimate of $18.53 million. CytomX Therapeutics had a negative net margin of 108.85% and a negative return on equity of 65.76%. During the same quarter in the prior year, the firm earned ($0.32) EPS. Equities research analysts expect that CytomX Therapeutics, Inc. will post -1.16 EPS for the current fiscal year.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W.

Featured Story: What is the Gross Domestic Product (GDP)?

Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics, Inc. (NASDAQ:CTMX).

Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.